{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schwannoma&page=3",
    "query": {
      "condition": "Schwannoma",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 69,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schwannoma&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Schwannoma&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T12:19:35.017Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04759781",
      "title": "MElanoma Research Lymph Node Prediction Implementation National_001",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "SkylineDx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1820,
      "start_date": "2021-08-25",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 9,
      "location_summary": "Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04759781"
    },
    {
      "nct_id": "NCT01119599",
      "title": "RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acoustic Schwannoma",
        "Adult Anaplastic (Malignant) Meningioma",
        "Adult Anaplastic Astrocytoma",
        "Adult Anaplastic Ependymoma",
        "Adult Brain Stem Glioma",
        "Adult Choroid Plexus Neoplasm",
        "Adult Craniopharyngioma",
        "Adult Diffuse Astrocytoma",
        "Adult Ependymoblastoma",
        "Adult Ependymoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Adult Grade I Meningioma",
        "Adult Grade II Meningioma",
        "Adult Medulloblastoma",
        "Adult Mixed Glioma",
        "Adult Myxopapillary Ependymoma",
        "Adult Oligodendroglioma",
        "Adult Papillary Meningioma",
        "Adult Pilocytic Astrocytoma",
        "Adult Pineal Gland Astrocytoma",
        "Adult Pineoblastoma",
        "Adult Pineocytoma",
        "Adult Primary Melanocytic Lesion of Meninges",
        "Adult Subependymal Giant Cell Astrocytoma",
        "Adult Subependymoma",
        "Adult Supratentorial Primitive Neuroectodermal Tumor",
        "Malignant Adult Intracranial Hemangiopericytoma"
      ],
      "interventions": [
        {
          "name": "3-Dimensional Conformal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2010-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-09-29",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 2,
      "location_summary": "New York, New York • Charlottesville, Virginia",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01119599"
    },
    {
      "nct_id": "NCT06517888",
      "title": "Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Vestibular Schwannoma"
      ],
      "interventions": [
        {
          "name": "AAVAnc80-antiVEGF via Akouos Delivery Device",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Akouos, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2025-01-17",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06517888"
    },
    {
      "nct_id": "NCT07503613",
      "title": "Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vestibular Schwannoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Akouos, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-03-02",
      "completion_date": "2040-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07503613"
    },
    {
      "nct_id": "NCT02811718",
      "title": "Resiliency Training for Patients With NF2 Via Videoconferencing With Skype",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neurofibromatosis 2"
      ],
      "interventions": [
        {
          "name": "Stress Management Group 1",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Stress Management Group 2",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2016-07",
      "completion_date": "2018-07",
      "has_results": false,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02811718"
    },
    {
      "nct_id": "NCT03542773",
      "title": "Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schwannomas",
        "Malignant Tumors"
      ],
      "interventions": [
        {
          "name": "18F-DCFPyL Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 38,
      "start_date": "2015-02-06",
      "completion_date": "2022-05-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03542773"
    },
    {
      "nct_id": "NCT01083966",
      "title": "Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Vestibular Schwannoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab (Avastin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-08",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083966"
    },
    {
      "nct_id": "NCT06322342",
      "title": "Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System (CNS) Lesions",
        "Brain Metastases",
        "Brain Neoplasms",
        "Brain Neoplasms, Benign",
        "Brain Tumor, Primary",
        "Brain Tumor, Recurrent",
        "Brain Tumors",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Neoplasm, Primary",
        "Multiple Sclerosis",
        "Multiple Sclerosis Brain Lesion",
        "Neurofibroma",
        "Acoustic Neuroma",
        "CNS Tumor",
        "CNS Lesion",
        "CNS Metastases",
        "CNS Cancer",
        "CNS Lymphoma",
        "Von Hippel Lindau",
        "Meningioma",
        "Glioma",
        "Schwannomas",
        "Neuroinflammation",
        "Neoplasia"
      ],
      "interventions": [
        {
          "name": "RVP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reveal Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-15",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06322342"
    },
    {
      "nct_id": "NCT05139277",
      "title": "Evaluation of the CONVIVO System",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioblastoma",
        "Glial Tumor",
        "Brain Metastases",
        "Meningioma",
        "Schwannoma",
        "Pituitary Tumor"
      ],
      "interventions": [
        {
          "name": "CONVIVO system",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Conventional histologic evaluation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-06-28",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05139277"
    },
    {
      "nct_id": "NCT04374305",
      "title": "Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurofibromatosis Type 2",
        "Vestibular Schwannoma",
        "Non-vestibular Schwannoma",
        "Meningioma",
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Neratinib",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scott R. Plotkin, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 109,
      "start_date": "2020-06-20",
      "completion_date": "2030-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-04T12:19:35.017Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Miami, Florida • Indianopolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianopolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04374305"
    }
  ]
}